Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study
Pharmacological inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) is an established therapeutic option to treat hypercholesterolemia, and plasma PCSK9 levels have been implicated in cardiovascular disease incidence. A number of genetic variants within the PCSK9 gene locus have been...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-09-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2021.728526/full |
| _version_ | 1818662049318699008 |
|---|---|
| author | Isabela Bensenor Kallyandra Padilha Isabella Ramos Lima Raul Dias Santos Gilles Lambert Stéphane Ramin-Mangata Marcio S Bittencourt Alessandra C Goulart Itamar S. Santos Jose G Mill Jose E Krieger Paulo A. Lotufo Alexandre C. Pereira |
| author_facet | Isabela Bensenor Kallyandra Padilha Isabella Ramos Lima Raul Dias Santos Gilles Lambert Stéphane Ramin-Mangata Marcio S Bittencourt Alessandra C Goulart Itamar S. Santos Jose G Mill Jose E Krieger Paulo A. Lotufo Alexandre C. Pereira |
| author_sort | Isabela Bensenor |
| collection | DOAJ |
| description | Pharmacological inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) is an established therapeutic option to treat hypercholesterolemia, and plasma PCSK9 levels have been implicated in cardiovascular disease incidence. A number of genetic variants within the PCSK9 gene locus have been shown to modulate PCSK9 levels, but these only explain a very small percentage of the overall PCSK9 interindividual variation. Here we present data on the genetic association structure between PCSK9 levels and genom-wide genetic variation in a healthy sample from the general population. We performed a genome-wide association study of plasma PCSK9 levels in a sample of Brazilian individuals enrolled in the Estudo Longitudinal de Saude do Adulto cohort (n=810). Enrolled individuals were free from cardiovascular disease, diabetes and were not under lipid-lowering medication. Genome-wide genotyping was conducted using the Axiom_PMRA.r3 array, and imputation was performed using the TOPMED multi-ancestry sample panel as reference. Total PCSK9 plasma concentrations were determined using the Quantikine SPC900 ELISA kit. We observed two genome-wide significant loci and seven loci that reached the pre-defined value of p threshold of 1×10−6. Significant variants were near KCNA5 and KCNA1, and LINC00353. Genetic variation at the PCSK9 locus was able to explain approximately 4% of the overall interindividual variations in PCSK9 levels. Colocalization analysis using eQTL data suggested RWDD3, ATXN7L1, KCNA1, and FAM177A1 to be potential mediators of some of the observed associations. Our results suggest that PCSK9 levels may be modulated by trans genetic variation outside of the PCSK9 gene and this may have clinical implications. Understanding both environmental and genetic predictors of PCSK9 levels may help identify new targets for cardiovascular disease treatment and contribute to a better assessment of the benefits of long-term PCSK9 inhibition. |
| first_indexed | 2024-12-17T04:54:46Z |
| format | Article |
| id | doaj.art-40ce06bc30634a589f2163df9294e2a7 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-12-17T04:54:46Z |
| publishDate | 2021-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-40ce06bc30634a589f2163df9294e2a72022-12-21T22:02:46ZengFrontiers Media S.A.Frontiers in Genetics1664-80212021-09-011210.3389/fgene.2021.728526728526Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil StudyIsabela Bensenor0Kallyandra Padilha1Isabella Ramos Lima2Raul Dias Santos3Gilles Lambert4Stéphane Ramin-Mangata5Marcio S Bittencourt6Alessandra C Goulart7Itamar S. Santos8Jose G Mill9Jose E Krieger10Paulo A. Lotufo11Alexandre C. Pereira12Center for Clinical and Epidemiologic Research, University of São Paulo, São Paulo, BrazilLaboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, BrazilLaboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, BrazilLipid Clinic, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, BrazilInserm UMR 1188 DéTROI, Université La Réunion, Sainte Clotilde, FranceInserm UMR 1188 DéTROI, Université La Réunion, Sainte Clotilde, FranceLipid Clinic, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, BrazilCenter for Clinical and Epidemiologic Research, University of São Paulo, São Paulo, BrazilCenter for Clinical and Epidemiologic Research, University of São Paulo, São Paulo, BrazilDepartment of Physiological Sciences, Federal University of Espírito Santo, Vitória, BrazilLaboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, BrazilCenter for Clinical and Epidemiologic Research, University of São Paulo, São Paulo, BrazilLaboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, BrazilPharmacological inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) is an established therapeutic option to treat hypercholesterolemia, and plasma PCSK9 levels have been implicated in cardiovascular disease incidence. A number of genetic variants within the PCSK9 gene locus have been shown to modulate PCSK9 levels, but these only explain a very small percentage of the overall PCSK9 interindividual variation. Here we present data on the genetic association structure between PCSK9 levels and genom-wide genetic variation in a healthy sample from the general population. We performed a genome-wide association study of plasma PCSK9 levels in a sample of Brazilian individuals enrolled in the Estudo Longitudinal de Saude do Adulto cohort (n=810). Enrolled individuals were free from cardiovascular disease, diabetes and were not under lipid-lowering medication. Genome-wide genotyping was conducted using the Axiom_PMRA.r3 array, and imputation was performed using the TOPMED multi-ancestry sample panel as reference. Total PCSK9 plasma concentrations were determined using the Quantikine SPC900 ELISA kit. We observed two genome-wide significant loci and seven loci that reached the pre-defined value of p threshold of 1×10−6. Significant variants were near KCNA5 and KCNA1, and LINC00353. Genetic variation at the PCSK9 locus was able to explain approximately 4% of the overall interindividual variations in PCSK9 levels. Colocalization analysis using eQTL data suggested RWDD3, ATXN7L1, KCNA1, and FAM177A1 to be potential mediators of some of the observed associations. Our results suggest that PCSK9 levels may be modulated by trans genetic variation outside of the PCSK9 gene and this may have clinical implications. Understanding both environmental and genetic predictors of PCSK9 levels may help identify new targets for cardiovascular disease treatment and contribute to a better assessment of the benefits of long-term PCSK9 inhibition.https://www.frontiersin.org/articles/10.3389/fgene.2021.728526/fullgenetic variationgenome-wide association studyatherosclerosisproprotein convertase subtilisin/kexin type 9colocalization analysis |
| spellingShingle | Isabela Bensenor Kallyandra Padilha Isabella Ramos Lima Raul Dias Santos Gilles Lambert Stéphane Ramin-Mangata Marcio S Bittencourt Alessandra C Goulart Itamar S. Santos Jose G Mill Jose E Krieger Paulo A. Lotufo Alexandre C. Pereira Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study Frontiers in Genetics genetic variation genome-wide association study atherosclerosis proprotein convertase subtilisin/kexin type 9 colocalization analysis |
| title | Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study |
| title_full | Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study |
| title_fullStr | Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study |
| title_full_unstemmed | Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study |
| title_short | Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study |
| title_sort | genome wide association of proprotein convertase subtilisin kexin type 9 plasma levels in the elsa brasil study |
| topic | genetic variation genome-wide association study atherosclerosis proprotein convertase subtilisin/kexin type 9 colocalization analysis |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2021.728526/full |
| work_keys_str_mv | AT isabelabensenor genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT kallyandrapadilha genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT isabellaramoslima genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT rauldiassantos genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT gilleslambert genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT stephaneraminmangata genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT marciosbittencourt genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT alessandracgoulart genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT itamarssantos genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT josegmill genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT joseekrieger genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT pauloalotufo genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy AT alexandrecpereira genomewideassociationofproproteinconvertasesubtilisinkexintype9plasmalevelsintheelsabrasilstudy |